Trial Profile
Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin as 1st Line Therapy (Post-HERMINE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2016
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Post-HERMINE
- Sponsors Roche
- 14 Apr 2011 New trial record